C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 7/06 (2006.01) A61K 35/14 (2006.01) C07K 14/47 (2006.01) C07K 14/705 (2006.01) C07K 16/30 (2006.01) A61K 38/00 (2006.01) A61K 39/00 (2006.01) C12N 5/08 (2006.01)
Patent
CA 2186006
The invention describes peptides derived from tumor rejection antigen precursor MAGE-2. Those peptides bind with HLA-A2 molecules, thus presenting complexes which provoke cytolytic T cell production. The resulting "CTLs" are specific for complexes of HLA-A2 and the peptide. The complexes can be used to generate monoclonal antibodies. The cytolytic T cells produced may be used in the context of immunotherapy, such as adoptive transfer.
On décrit des peptides, dérivés d'un précurseur d'antigène de rejet tumoral, MAGE-2, qui se lient avec des molécules HLA-A2, ce qui permet d'obtenir des complexes qui provoquent la production de lymphocytes T cytolytiques (LTC). Les LTC résultants sont spécifiques des complexes d'HLA-A2 et d'un tel peptide, complexes qui permettent de produire des anticorps monoclonaux. On peut utiliser les lymphocytes T cytolytiques ainsi produits dans le contexte d'une immunothérapie telle que le transfert adoptif.
Boon-Falleur Thierry
Kast W. M.
Melief Cornelis J. M.
Van Der Bruggen Pierre
Visseren M. W.
Ludwig Institute For Cancer Research
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
University Of Leiden
LandOfFree
Isolated tumor rejection antigen precursor mage-2 derived... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isolated tumor rejection antigen precursor mage-2 derived..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolated tumor rejection antigen precursor mage-2 derived... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2036802